Comparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic Patient

What this Trial Is About

Eosinophilia is a condition where the absolute eosinophil count exceeds 500 cells per microliter, with causes ranging from mild to severe diseases. Parasite infection is a common cause in developing countries, but current stool microscopy methods have low sensitivity, and more advanced tests can be costly and unavailable. This research aims to compare outcomes between specific anthelminthic treatment based on stool test results and empirical anthelminthic treatment without testing to address uncertainties in managing eosinophilic patients. Participants are randomly assigned to one of two groups. The specific treatment group provides stool samples for three days, tested by microscopy, culture, and PCR to detect parasites, and then receives anthelminthic treatment tailored to results. The empirical treatment group receives albendazole 400 mg twice daily for seven days without prior stool testing. Both groups are monitored for response to treatment over four weeks. During the study, participants undergo stool sample collection and analysis, followed by treatment. Blood tests including complete blood count are done to assess eosinophil levels before and after treatment. The main measurement is recovery from eosinophilia at four weeks after treatment. Researchers also track changes in absolute eosinophil count. The study runs until December 2025 and includes monitoring for safety and treatment responses throughout this period.

Specific Versus Empirical Anthelminthic Treatment in Eosinophilia